Table 1. Patient characteristics at baseline of enrollment (N=30).
| Characteristics | n (%) |
| ECOG, Eastern Cooperative Oncology Group; TNBC, triple-negative breast cancer; HR, hormonal receptor; IV, primary metastasis; DFS, disease-free survival. | |
| Median age (range) (year) | 49.5 (35−69) |
| ECOG performance status | |
| 0 | 25 (83.3) |
| 1 | 5 (16.7) |
| Molecular subtype | |
| TNBC | 10 (33.3) |
| HR+ | 20 (66.7) |
| Ki67 rate | |
| ≤50% | 17 (56.7) |
| >50% | 8 (26.6) |
| Unknown | 5 (16.7) |
| Tumor grade | |
| Grade II | 14 (46.7) |
| Grade III | 12 (40.0) |
| Unknown | 4 (13.3) |
| No. of lymph node | |
| No | 11 (36.7) |
| Yes | 13 (43.3) |
| IV | 6 (20.0) |
| DFS (month) | |
| ≤36 | 19 (63.3) |
| >36 | 11 (36.7) |
| Chemotherapy prior enrollment | |
| No | 0 (0) |
| Yes | 30 (100) |
| Endocrine therapy prior enrollment | |
| No | 10 (33.3) |
| Yes | 20 (66.7) |
| Radiation therapy prior enrollment | |
| No | 10 (33.3) |
| Yes | 14 (46.7) |
| IV | 6 (20.0) |
| No. of metastatic sites | |
| 1 | 13 (43.3) |
| 2 | 11 (36.7) |
| ≥3 | 6 (20.0) |
| Invasive metastasis | |
| No | 25 (83.3) |
| Yes | 5 (16.7) |
| Line of disease prior enrollment | |
| 1 | 4 (13.3) |
| 2 | 10 (33.3) |
| ≥3 | 16 (53.3) |
| Combined drug | |
| No | 10 (33.3) |
| Tamoxifen | 3 (10.0) |
| Aromatase inhibitor | 13 (43.4) |
| Fulvestrant | 4 (13.3) |